Contact Us Contact Us Contact Us

Updated July 2026

Pharma Guide · Buyer Checklist

6 things to check before choosing an injection manufacturer in India

With over 500 WHO-GMP certified pharmaceutical facilities in India (CDSCO, 2024-25), choosing the right injection manufacturer in India is not just about price. Six specific checks determine whether your supply chain will pass international drug registration — or fail at the regulator’s desk.

  • 10 companies reviewed
  • WHO-GMP verified criteria
  • 14 min read

  • WHO-GMP Status

    Active cert — not expired

  • Sample COA

    real batch data, 24 hours

  • DCGI Approvals

    molecule-level approval

  • COPP on file

    for your target country

  • Grade A/B cleanroom

    sterile injectable

  • Written by

    Bhavya Bhambani

    Content Writer, 9M India

  • Reviewed by

    Manish Agrawal

    MD, 9M India Limited

  • Fact-checked by

    Manish Shah

    Plant Head, 9M India

About 9M India Limited — examples and standards referenced in this guide

9M India Limited is a WHO-GMP certified pharmaceutical manufacturer established in 2009, located in Birkoni, District Mahasamund, Chhattisgarh. The company operates a Grade A/B classified sterile manufacturing facility with DCGI-approved manufacturing licences for 200+ injectable molecules. This guide uses 9M India’s documentation standards as the benchmark — COPP, FSC, COA, and stability data available within 24 hours, exports to 15+ countries.

Why these 6 checks matter — industry context

India is the world’s largest exporter of generic medicines by volume, with pharmaceutical exports reaching $27.9 billion in FY2024 (Pharmexcil, 2024). The country has over 500 WHO-GMP certified manufacturing facilities registered with CDSCO (CDSCO Annual Report, 2024-25). Of these, a significantly smaller subset operate the Grade A/B sterile cleanrooms required for injectable pharmaceutical manufacturing. International buyers — particularly in Africa, Middle East, CIS, and South-East Asia — face a verification challenge: many facilities claim WHO-GMP compliance without meeting the sterile manufacturing standards that export regulatory authorities specifically require. These six checks are the practical buyer’s verification framework, drawn from the documentation requirements of NAFDAC (Nigeria), KEBS/PPB (Kenya), MOH UAE, SFDA (Saudi Arabia), and WHO prequalification guidelines.

WHO-GMP Certification

Verify the WHO-GMP certificate expiry date — not just the existence of a certificate

The most common buyer mistake is confirming that a WHO-GMP certificate exists without checking whether it is currently valid.

#1 of 6

When sourcing from an injection manufacturer in India, request the actual WHO-GMP certificate document — not a reference to it, not a website badge, not a verbal assurance. The certificate must show the facility name, manufacturing site address, manufacturing licence number, the dosage forms covered (specifically sterile injectables), the issue date, and the expiry date. WHO-GMP certificates in India are issued by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Government of India, following an on-site inspection conducted against World Health Organization Good Manufacturing Practice guidelines.

WHO-GMP certificates are not permanent. They carry an expiry date after which the certificate is no longer valid for export registration purposes. A manufacturer whose WHO-GMP certificate has expired – even by one day – has not undergone the required re-inspection and cannot certifiably claim current compliance. Import regulatory authorities in Africa, Middle East, CIS, and South-East Asia will reject drug registration dossiers that cite an expired WHO-GMP certificate.

What is WHO-GMP certification in India?

WHO-GMP (World Health Organization Good Manufacturing Practice) is a pharmaceutical-specific manufacturing standard that covers facility design, cleanroom classification, water purification systems, air handling, personnel hygiene, manufacturing process validation, analytical quality control testing, batch documentation, and batch release. In India, WHO-GMP certificates are issued by CDSCO following an inspection of the manufacturing facility. The certificate is time-limited and must be renewed through periodic re-inspection. It is distinct from ISO 9001, which is a general quality management system and is not accepted for pharmaceutical export drug registration.

How to verify - step by step

  • Request the actual document: Ask for a PDF or scan of the WHO-GMP certificate. It should be on official CDSCO letterhead with an authorised signature and stamp.

  • Check the expiry date explicitly: Do not accept a certificate without a visible expiry date. If the certificate does not show an expiry, contact CDSCO directly to verify current status.

  • Confirm dosage forms covered: The certificate must specifically list “sterile injectables” or equivalent – a general site WHO-GMP certificate that excludes sterile manufacturing is not sufficient for injectable procurement.

  • Cross-verify on CDSCO database: CDSCO maintains a searchable database of licensed manufacturers at cdsco.gov.in. Cross-reference the manufacturer’s name and licence number to confirm active status.

Why this check matters for export

NAFDAC (Nigeria), KEBS (Kenya), MOH UAE, and SFDA (Saudi Arabia) all require submission of a valid, unexpired WHO-GMP certificate as part of pharmaceutical product registration. A certificate expired at the time of dossier submission is grounds for automatic rejection – requiring resubmission and potentially a new inspection cycle, adding months or years to registration timelines.

Red flags to watch for

Certificate older than 3 years with no re-inspection documentation. Certificate does not list sterile dosage forms. Manufacturer cannot provide certificate within 24 hours of being asked. Certificate shows a manufacturing site address different from where your products will be made.

DCGI Approval

Confirm DCGI molecule-level approval — the check most buyers miss entirely

WHO-GMP certifies the building. DCGI approves the product. You need both — and most buyers only ask for one.

#2 of 6

The WHO-GMP certificate covers the manufacturing facility as a whole — it confirms that the site meets Good Manufacturing Practice standards. It does not, by itself, authorise the commercial manufacture of any specific drug product. The Drug Controller General of India (DCGI) issues separate manufacturing licences for individual drug products — specifying the molecule, salt form, strength, dosage form, and pack size that the manufacturer is legally authorised to produce. An injection manufacturer in India without a DCGI manufacturing licence for your specific molecule cannot legally manufacture that product for commercial supply, regardless of their WHO-GMP status.

Why this distinction matters

India has multiple regulatory layers for pharmaceutical manufacturing. The State Drug Control Authority issues a Form 27/27B manufacturing licence (prerequisite for WHO-GMP). The DCGI adds product-specific approval. Both levels apply to sterile injectable manufacturing. Buying from a manufacturer who holds a facility WHO-GMP but lacks DCGI product approval means you may receive products manufactured without legal authorisation — a serious regulatory and quality risk for your market registration.

How to verify DCGI molecule-level approval

  • Request the manufacturing licence: Ask for a copy of the DCGI manufacturing licence (or State Licence Form 27D for sterile products) specifically listing your molecule, strength, and dosage form.

  • Check the product-specific approval: The licence should list individual approved products. Your molecule should appear explicitly — not just the general category “injectables”.

  • Verify schedule classification: Most injectables fall under Schedule C or C1. Certain injectables (cytotoxics) are Schedule L1. Confirm the manufacturer holds the correct schedule classification for your product.

Red flags to watch for

Certificate older than 3 years with no re-inspection documentation. Certificate does not list sterile dosage forms. Manufacturer cannot provide certificate within 24 hours of being asked. Certificate shows a manufacturing site address different from where your products will be made.

#1 injection manufacturer in India 2026

Dummy Content

Share your molecule, strength, pack format, and target market. We confirm manufacturing capability, pricing, and all export documentation within 24 hours.

  • 00+ injectable molecules — ampoules, vials, IV, lyophilised
  • COPP, FSC, COA, stability data — all within 24 hours
  • Contract manufacturing and third-party manufacturing both available
  • Active export to Africa, Middle East, CIS, South-East Asia
Talk to 9M India

Certificate of Analysis

Request a sample Certificate of Analysis within 24 hours — & know what to look for

A genuine injection manufacturer in India holds batch release data and can share a sample COA immediately. Delay is a red flag.

#3 of 6

A Certificate of Analysis (COA) is the batch-level quality document that proves a specific production batch of an injectable product has been tested and meets all specifications before release for distribution. A legitimate injection manufacturer company in India generates a COA for every manufactured batch as part of its WHO-GMP batch release process. A sample COA — showing real batch data, not a blank template — should be available within 24 hours of any buyer’s request.

What a complete injectable COA must contain

Parameter Why it matters Specification example
Assay (potency) Confirms active ingredient is at label strength 95.0%-105.0% of label claim (BP/USP)
Sterility test Confirms no microbial contamination Complies – no growth (BP/USP sterility method)
Bacterial endotoxins Confirms absence of fever-causing pyrogens Less than 0.25 EU/mL (WHO guideline)
pH Confirms stability and patient tolerability Typically 3.5-7.5 (product-specific specification)
Clarity and colour Checks for visible particles or discolouration Clear, colourless to pale yellow – complies BP
Particulate matter Sub-visible particles – patient safety check ≤6000 particles ≥10µm per container (BP)
Container integrity Confirms no leakage or seal failure Complies – no failures in leak test
Container integrity Traceability Batch number, mfg date, expiry date
QP signature Authorised release Signed by Qualified Person with designation

Why this check matters for export

NAFDAC (Nigeria), KEBS (Kenya), MOH UAE, and SFDA (Saudi Arabia) all require submission of a valid, unexpired WHO-GMP certificate as part of pharmaceutical product registration. A certificate expired at the time of dossier submission is grounds for automatic rejection – requiring resubmission and potentially a new inspection cycle, adding months or years to registration timelines.

Red flags to watch for

Certificate older than 3 years with no re-inspection documentation. Certificate does not list sterile dosage forms. Manufacturer cannot provide certificate within 24 hours of being asked. Certificate shows a manufacturing site address different from where your products will be made.

From the Compare section

WHO-GMP vs ISO 9001 — does certification type affect COA quality?

COA requirements for sterile injectables — sterility test, bacterial endotoxin, particulate matter — are pharma-specific standards that only WHO-GMP covers. ISO 9001 does not specify these tests. An ISO 9001 certified injection manufacturer may not run bacterial endotoxin testing at all.

Complete COA
WHO-GMP certified facility

Sterility · Bacterial endotoxin · Particulate matter · Assay · pH — all required and documented per WHO-GMP batch release procedure.

  • All tests mandatory for batch release
ISO 9001 only facility

Sterility · Bacterial endotoxin · Particulate matter · Assay · pH — all required and documented per WHO-GMP batch release procedure.

  • Pharma-specific tests not mandated
Read Full Comparison

Export References & COPP

Ask for export references in your specific target country — an existing COPP saves 6–12 months

If the injection manufacturer has already registered products in your market, your registration timeline shrinks dramatically.

#4 of 6

A Certificate of Pharmaceutical Product (COPP) is an official document issued by the CDSCO (Central Drugs Standard Control Organisation), Government of India, confirming that a specific pharmaceutical product is authorised for manufacture and sale in India. Most export drug registration authorities — NAFDAC, TFDA, PPB, MOH UAE, SFDA, FDA Myanmar — require a valid COPP from the country of manufacture as part of the drug registration dossier.

If an injection manufacturer in India has already exported to your target country and holds an active COPP for that market, their existing dossier can be referenced in your registration application. This can reduce drug registration timelines by 6–12 months — particularly in Africa and Middle East where dossier review queues are long and missing documents require complete resubmission.

What is a COPP (Certificate of Pharmaceutical Product)?

A COPP is issued under the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. In India, CDSCO issues COPPs for products that are: (1) manufactured by a DCGI-licensed manufacturer at a WHO-GMP certified facility, and (2) registered and approved for commercial sale in India. The COPP confirms the product’s regulatory status, manufacturing site, WHO-GMP status, and dosage form. It is one of the primary documents required for drug registration in most pharmaceutical import countries. (WHO Technical Report Series No. 986, Annex 10)

Questions to ask about export references

  • “Have you previously exported to [country]?” — and ask for the name of the registered product and the year of first registration.

  • “Do you hold an active COPP for [country]?” — ask to see the COPP document, confirming it covers your molecule.

  • “Can you provide a CTD or ACTD dossier for registration?” — a manufacturer with export experience typically holds ready-to-submit dossiers that significantly reduce your preparation burden.

Countries where 9M India currently holds export registrations

9M India Limited exports actively to 15+ countries including Kenya, Nigeria, Yemen, Colombia, Venezuela, Sierra Leone, Azerbaijan, Myanmar, and Nepal. For buyers targeting these markets, COPP and dossier support is available within 24 hours. For new markets, 9M India supports full dossier preparation.

Cleanroom Grade

Confirm Grade A/B cleanroom classification — non-negotiable for sterile injectable manufacturing

Cleanroom grade determines whether a facility can legally and safely manufacture sterile injectables. Grade C is insufficient.

#5 of 6

In pharmaceutical sterile manufacturing, cleanrooms are classified under EU GMP Annex 1 and WHO GMP guidelines according to airborne particle counts and microbial contamination limits. For injectable pharmaceutical products — ampoules, vials, IV infusions, lyophilised products — WHO-GMP mandates specific cleanroom grades at each stage of the manufacturing process.

Ask the injection manufacturer company in India for their cleanroom validation report or EU/WHO GMP Annex 1 compliance documentation. The Grade A/B classification must be validated through a particle count study and environmental monitoring programme — not just claimed. A facility without documented Grade A/B validation cannot demonstrate sterile manufacturing compliance to an import regulatory authority.

9M India’s Birkoni facility operates a Grade A/B classified sterile cleanroom for injectable fill-finish operations. The facility runs a continuous environmental monitoring programme covering viable and non-viable airborne particle counts, surface contamination monitoring, and personnel monitoring — all documented per WHO-GMP Annex 1 requirements.

Cleanroom grade requirements for injectable manufacturing

Cleanroom Grade Use in injectable manufacturing Required for commercial sterile
Grade A Aseptic fill zone — direct product exposure area. Also used for critical operations such as stopper transfer and container assembly. ✓ Mandatory for fill zone
Grade B Background environment surrounding Grade A. Personnel work in Grade B when conducting Grade A operations. ✓ Mandatory — surrounds Grade A
Grade C Preparation of solutions to be filtered before filling. Less critical stages of manufacturing. Support areas only
Grade D Background for less critical work. Gowning areas, equipment washing. Support areas only
No classification General manufacturing area — non-sterile dosage forms (tablets, capsules) X Cannot produce sterile injectables

Red flags

Manufacturer cannot produce cleanroom validation documentation · Claims WHO-GMP but cannot confirm Grade A/B classification · Environmental monitoring data (viable and non-viable particle counts) not available on request · WFI (Water for Injection) system not present — WFI is mandatory for sterile injectable manufacturing

Documentation Turnaround

Test documentation turnaround time — 24 hours is the benchmark that separates serious manufacturers

The speed at which a manufacturer produces documentation reveals the depth of their regulatory readiness — before you sign any contract.

#6 of 6

Documentation turnaround time is a practical proxy for a manufacturer’s regulatory maturity. A well-organised, genuinely WHO-GMP compliant injection manufacturer in India maintains all documentation in a structured, readily accessible system. WHO-GMP certificate, DCGI manufacturing licence, COPP, FSC, sample COA, and stability data should all be retrievable and shareable within 24 hours of a serious buyer’s request — not in “a few days” or “next week”.

At 9M India, all documentation for products in active production — WHO-GMP certificate, COPP, FSC, COA, stability data, and CTD dossier support — is available within 24 hours. This is a stated commitment, not a target. Buyers can test this at any time before placing an order.

The documentation turnaround test — run this before any purchase order

  • Send a documentation request by email at 9 AM: Ask for WHO-GMP certificate, sample COA for one molecule, and confirmation of DCGI approval. A benchmark manufacturer responds by end of business on the same day.

  • Ask for COPP and stability data: These require slightly more preparation but should be with you within 24 hours for existing export products. More than 48 hours indicates the documents may not exist or are not maintained centrally.

  • Request an ICH Zone IVb stability report: Long-term stability data under 30°C/75% relative humidity conditions — required by most tropical-climate importing countries. A manufacturer who has been exporting should have this for every product in their export range.

What slow turnaround reveals

Documentation delays typically indicate: documents are prepared by a third-party regulatory consultant rather than maintained in-house, the product is not genuinely in regular commercial production, the WHO-GMP or DCGI approval is not current, or the facility lacks a proper document management system. Any of these scenarios represents a supply chain risk for a serious buyer. A manufacturer who takes 2 weeks to provide a COA will take 6 months to resolve a batch quality dispute.

More Pharma Guide

Frequently asked questions

  • How do I verify a WHO-GMP certificate for an Indian injection manufacturer?

    To verify a WHO-GMP certificate for an injection manufacturer in India, request the actual certificate document — not a website reference. The certificate should be on CDSCO official letterhead and show: facility name, manufacturing site address, manufacturing licence number, specific dosage forms covered (must include sterile injectables), issue date, and expiry date. You can cross-reference independently at cdsco.gov.in using the manufacturer’s name and licence number. The certificate must be current — not expired. For additional verification, buyers can contact CDSCO’s WHO-GMP certification unit directly at the Ministry of Health and Family Welfare, Government of India.

    Reference: Central Drugs Standard Control Organisation (CDSCO), Government of India · WHO Technical Report Series No. 986, 2014

  • What is the difference between WHO-GMP facility certification and DCGI molecule approval?

    WHO-GMP certification covers the entire manufacturing facility — its physical design, cleanroom classification, equipment, personnel training, manufacturing processes, quality control laboratory, and batch documentation systems. It is issued by CDSCO at the site level and confirms the facility meets WHO Good Manufacturing Practice standards. DCGI manufacturing approval (manufacturing licence) is product-specific — it authorises the commercial manufacture of a named drug molecule at a specified strength and dosage form, at that specific licensed facility. An injection manufacturer in India can hold WHO-GMP certification for the site but still require a separate DCGI product-level licence for each molecule they commercially manufacture. Both are required: the WHO-GMP certificate demonstrates facility quality standards; the DCGI licence demonstrates legal authorisation to manufacture the specific product you are buying.

  • What should a pharma Certificate of Analysis for injectables contain?

    A complete Certificate of Analysis (COA) for injectable pharmaceutical products must contain: batch number, manufacturing date, expiry date, assay (potency as percentage of label claim — typically 95%–105%), sterility test result (pass against BP or USP method), bacterial endotoxin test result in EU/mL (the endotoxin limit for most injectables is ≤0.25 EU/mL under WHO guidelines), pH value with specification range, clarity and colour evaluation, sub-visible particulate matter results (≤6000 particles ≥10µm per container and ≤600 particles ≥25µm per container under BP method), container integrity test result, and the authorised signature of the releasing Qualified Person. All results should show the actual numerical value obtained alongside the specification — not just “Pass” or “Complies”.

    (British Pharmacopoeia 2024 · WHO Technical Report Series No. 961)

  • What is Grade A/B cleanroom & why is it mandatory for injection manufacturing?

    Cleanrooms in pharmaceutical manufacturing are classified under EU GMP Annex 1 (or equivalent WHO GMP guidelines) into Grades A, B, C, and D based on maximum permitted airborne particle concentrations and microbial contamination limits. Grade A — the highest classification — is the zone where sterile product is directly exposed to the manufacturing environment, including the fill zone for injectable ampoules, vials, and IV bags. At rest, Grade A allows a maximum of 3,520 particles per cubic metre at ≥0.5µm. Grade B is the background environment surrounding Grade A, where personnel operate during aseptic fill procedures. For commercial sterile injectable manufacturing — ampoules, glass vials, IV infusions, lyophilised products — WHO-GMP mandates Grade A at the point of fill and Grade B as the surrounding environment. A facility without validated Grade A/B cleanroom classification cannot manufacture sterile injectables in compliance with WHO-GMP and cannot satisfy the sterile manufacturing requirements of import regulatory authorities.

    (WHO Technical Report Series No. 1044, Annex 1 · EU GMP Annex 1, 2022)

  • How long does it take to get a COPP from India for a specific injection product?

    A Certificate of Pharmaceutical Product (COPP) for an injectable medicine from India is issued by CDSCO under the WHO Certification Scheme. For manufacturers holding an existing DCGI manufacturing licence and valid WHO-GMP certificate, a fresh COPP application to CDSCO typically takes 30–90 days from submission to issuance, depending on the current docket workload. However, manufacturers who have previously exported to specific countries — and who have held COPPs for those markets — typically hold active COPPs that can be provided to a new buyer within 24–48 hours. This is why checking for existing export references in your target country (Check 4 in this guide) is practically important: an existing COPP on file eliminates the 30–90 day waiting period and allows your drug registration submission to proceed immediately.

    (WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce · WHO Technical Report Series No. 986, Annex 10)

9M India — passes all 6 checks

Ready to verify 9M India against your checklist?

WHO-GMP certificate, DCGI approval, sample COA, COPP, stability data — all available within 24 hours of your first enquiry.

Send an enquiry
View injection range
WhatsApp

WHO-GMP certified · DCGI approved · 15+ export countries · Birkoni, Chhattisgarh · Est. 2009

By Formulation Type
Tablets Capsules Granules & Powders Syrups Suspensions Solutions Ointments Creams Gels Injections Eye Drops Ear Drops External Liquid Dosage
By Therapeutic Segment
Antibiotics Pain Management Cardiovascular Diabetic Care CNS / Neurology Gastrointestinal Respiratory Dermatology Vitamins & Minerals Ophthalmic Paediatrics Anti Infective

Looking for something specific?

At 9M India Limited, trust through quality, transparency, performance.

Get In Touch With Us

Contract Manufacturing

Contract Manufacturing

3rd Party Manufacturing

3rd Party Manufacturing

Institutional Tenders

Institutional Tenders

Generic Medicines

Generic Medicines

OTC Products

OTC Products

Regulatory Services

QC & QA